免疫治疗联合抗血管生成治疗在晚期非小细胞肺癌患者中的应用效果  

Application effect of immunotherapy combined with anti-angiogenic therapy in patients with advanced non-small cell lung cancer

作　　者：雷彬花 田春桃[1] 苏静[1] LEI Binhua;TIAN Chuntao;SU Jing(Department of Medical Oncology,Sanmenxia Central Hospital,Sanmenxia 472000,He’nan,China)

机构地区：[1]三门峡市中心医院肿瘤内科,河南三门峡472000

出　　处：《癌症进展》2024年第4期395-399,共5页Oncology Progress

基　　金：三门峡市2022年科技发展计划项目(2022002092)。

摘　　要：目的探讨免疫治疗联合抗血管生成治疗在晚期非小细胞肺癌(NSCLC)患者中的应用效果。方法依据治疗方法的不同将82例晚期NSCLC患者分为观察组(n=49)和对照组(n=33),两组均给予化疗,在此基础上,对照组患者接受抗血管生成药物贝伐珠单抗治疗,观察组患者接受卡瑞利珠单抗联合贝伐珠单抗治疗。比较两组患者的临床疗效、T淋巴细胞亚群(CD3+、CD4+、CD4+/CD8+)、炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]、生活质量[卡氏功能状态(KPS)评分]及不良反应发生情况。结果观察组患者的客观缓解率为34.69%,高于对照组患者的12.12%(P﹤0.05),疾病控制率为87.76%,高于对照组患者的66.67%(P﹤0.05)。治疗后,两组患者CD3+、CD4+水平和CD4+/CD8+均高于本组治疗前,观察组患者CD3+、CD4+水平和CD4+/CD8+均高于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者TNF-α、IL-6水平均低于本组治疗前,KPS评分均高于本组治疗前,观察组患者TNF-α、IL-6水平均低于对照组,KPS评分高于对照组,差异均有统计学意义(P﹤0.05)。两组患者不良反应发生率比较,差异均无统计学意义(P﹥0.05)。结论免疫治疗联合抗血管生成治疗对晚期NSCLC的治疗效果较好,可改善机体免疫功能,减轻炎症反应,提高生活质量,安全性相对较高。Objective To explore the application effect of immunotherapy combined with anti-angiogenic therapy in patients with advanced non-small cell lung cancer(NSCLC).Method According to different treatment methods,82 patients with advanced NSCLC were divided into observation group(n=49)and control group(n=33).Both groups were given chemotherapy,the control group received anti-angiogenic drug bevacizumab therapy,and the observation group received camrelizumab combined with bevacizumab therapy.The clinical efficacy,T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+),inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)],quality of life[Karnofsky performance status(KPS)score],and incidence of adverse reactions were compared between two groups.Result The objective response rate of the observation group was 34.69%,which was higher than 12.12%of the control group(P<0.05),and the disease control rate was 87.76%,which was higher than 66.67%of the control group(P<0.05).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+in both groups were higher than those before treatment,the levels of CD3+,CD4+,and CD4+/CD8+in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of TNF-αand IL-6 in both groups were lower than those before treatment,and the KPS scores were higher than those before treatment,the levels of TNF-αand IL-6 in the observation group were lower than those in the control group,and the KPS score was higher than that in the control group,the differences were statistically significanant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Immunotherapy combined with anti-angiogenesis therapy has a good effect in the treatment of advanced NSCLC,which can improve immune function,reduce inflammation,improve quality of life,and is relatively safe.

关 键 词：晚期非小细胞肺癌 免疫治疗 抗血管生成治疗 免疫功能 炎性因子 

分 类 号：R734.2[医药卫生—肿瘤]